Emily Bodnar

Emily Bodnar has a diverse work experience in the finance industry. Emily started their career as an Accounts Payable Clerk at Castle Brands Inc. from June 2015 to August 2017. Emily then worked as an Asset Management Summer Analyst at Rothschild & Co from June 2018 to August 2018. Emily then joined Berenberg Capital Markets as a Biotech Equity Research Associate from June 2019 to September 2020. After that, they worked at Cantor Fitzgerald as a Biotech Equity Research Associate from September 2020 to December 2021. Currently, they hold the position of Vice President Equity Research Analyst at H.C. Wainwright & Co., LLC starting from January 2022.

Emily Bodnar has a Bachelor's Degree in Finance from Binghamton University School of Management. Additionally, they have completed courses in innate immunity and B-cell function, T cells and signaling, and death by friendly fire at Rice University. Emily has also taken a course titled Introduction to the Biology of Cancer (with Honors) at The Johns Hopkins University. In terms of certifications, Emily has obtained the Series 86, Series 87, Series 63, and Series 7 from FINRA, with their most recent certification being the Series 86 obtained in March 2020.